IL9R

Across TCGA pan-cancer cohorts, IL9R Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IL9R data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IL9R Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL9R expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

HNSC, LUAD, and UCEC are the cancer types where IL9R Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.102	0.733	<.001	18	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →
SCLC	DFS	Median	II,III,IV	1.000	0.305	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IL9R–HNSC (OS)

Open the HNSC breakdown →